Staar Surgical Company (NASDAQ: STAA) has announced the postponement of its special meeting of stockholders in connection with the company's merger agreement with Alcon (SIX/NYSE: ALC) to December 3, 2025, at 8:30 a.m. Pacific time. The new record date for the special meeting is the close of business on October 24, 2025.
Staar Surgical, the global leader in implantable phakic intraocular lenses, has been dedicated solely to ophthalmic surgery since 1982. The company's proprietary biocompatible collamer material is used in its advanced implantable collamer lenses (ICLs), which are clinically proven to provide safe long-term vision correction without the need to remove corneal tissue or the eye's natural crystalline lens. The company's Evo ICL™ product line offers visual freedom through a quick, minimally invasive procedure.
Staar Surgical has sold more than 3 million ICLs in over 75 countries and operates research, development, manufacturing, and packaging facilities in California and Switzerland.
This announcement comes in light of ongoing discussions with Alcon, and the company will be providing a notice of the meeting and other materials to stockholders in advance of the new meeting date.
Stockholders who hold shares as of the record date will be eligible to vote at the postponed special meeting on December 3, 2025. For questions about voting their shares, stockholders are advised to contact Staar's proxy solicitor, Innisfree M&A Incorporated, toll-free at +1 877-750-8233. Banks and brokerage firms are requested to call +1 212-750-5833. As a result of these announcements, the company's shares have moved -2.56% on the market, and are now trading at a price of $26.27. For the full picture, make sure to review STAAR SURGICAL CO's 8-K report.
